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Potent and selective chemical probe of hypoxic
signalling downstream of HIF-a hydroxylation
via VHL inhibition
Julianty Frost1,*, Carles Galdeano1,*,w, Pedro Soares1, Morgan S. Gadd1, Katarzyna M. Grzes2, Lucy Ellis1,
Ola Epemolu1, Satoko Shimamura3, Marcus Bantscheff3, Paola Grandi3, Kevin D. Read1, Doreen A. Cantrell2,
Sonia Rocha4 & Alessio Ciulli1
Chemical strategies to using small molecules to stimulate hypoxia inducible factors (HIFs)
activity and trigger a hypoxic response under normoxic conditions, such as iron chelators and
inhibitors of prolyl hydroxylase domain (PHD) enzymes, have broad-spectrum activities
and off-target effects. Here we disclose VH298, a potent VHL inhibitor that stabilizes
HIF-a and elicits a hypoxic response via a different mechanism, that is the blockade of the
VHL:HIF-a protein–protein interaction downstream of HIF-a hydroxylation by PHD enzymes.
We show that VH298 engages with high afﬁnity and speciﬁcity with VHL as its only major
cellular target, leading to selective on-target accumulation of hydroxylated HIF-a in a
concentration- and time-dependent fashion in different cell lines, with subsequent
upregulation of HIF-target genes at both mRNA and protein levels. VH298 represents a
high-quality chemical probe of the HIF signalling cascade and an attractive starting point to
the development of potential new therapeutics targeting hypoxia signalling.
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S
mall molecules that bind potently and selectively to their
protein target inside the cell can be high-value chemical
tools, complementary to genetic approaches, to study
and perturb biological systems. In recent years, development of
high-quality chemical probes has enabled signiﬁcant progress in
both basic and translational research, and has furnished suitable
start points for drug development1,2. One area that is seeing
increasing interest for chemical biology and drug discovery
applications is the pharmacological modulation of oxygen
sensing3,4, one of the most fundamental processes in aerobic
organisms5. Studying the cell’s adaptive responses to low oxygen
levels via the hypoxic signalling pathway has provided important
insights to aid understanding of oxygen sensing6,7. Thus the
ability to induce hypoxic signalling in a selective fashion using
chemical probes with deﬁned mechanism of action could lead to
new biological insights, the chemical validation of potential drug
targets, and the development of new therapeutics.
Hypoxia inducible factors (HIFs), the master regulators of
hypoxic signalling, are a family of oxygen-sensitive transcription
factors composed of an oxygen-labile a-subunit HIF-a (of which
three paralogs are known: HIF-1a, HIF-2a and HIF-3a)
and a constitutively stable b-subunit (HIF-b)7. HIF-a, among
which HIF-1a and HIF-2a are predominant, are maintained
at very low levels under normoxia as a result of highly efﬁcient
polyubiquitination by the von Hippel–Lindau (VHL) Cullin
RING E3 ubiquitin ligase complex (CRL2VHL) and subsequent
proteasomal degradation8–10. Key to the highly speciﬁc molecular
recognition of HIF-a by VHL is the post-translational
hydroxylation of key HIF-a proline residues by the oxygen-
dependent activity of prolyl hydroxylase domain (PHD)
enzymes11–14. In contrast, under low oxygen levels HIF-a
proteins remain unhydroxylated, escape VHL recognition and
proteasomal degradation, and form heterodimeric complexes
with HIF-b that bind to a speciﬁc core DNA motif known as
hypoxia response elements (HREs)15. Transcriptionally active
HIFs induce the expression of a wide range of genes linked to key
biological processes including angiogenesis, cell proliferation,
glucose uptake and anaerobic metabolism, ultimately promoting a
hypoxic response6,16,17.
Several chemical agents stabilize HIF-a and induce a hypoxic
response even under normoxic conditions. Examples of
hypoxia mimetic agents include Fe2þ substitutes (Co2þ ,
Ni2þ )18; 2-oxoglutarate mimics such as dimethyloxalylglycine,
N-oxalylglycine and N-oxalyl-D-phenylalanine19,20; Fe2þ
chelators (deferoxamine also known as desferrioxamine, and
AKB-4924)18,21; inhibitors of PHD enzymes, for example, IOX2
(ref. 22) and the phase 3 clinical trial compound roxadustat
(FG-4592)23; inhibitors of cullin neddylation (MLN4924)24,25;
and proteasome inhibitors26. Although widely used in biochemical
and biomedical research, these reagents have poor target selectivity
and affect multiple pathways, severely limiting their scope as
chemical probes of hypoxic signalling. Here, we describe VH298,
a novel potent chemical probe that triggers the hypoxic response
via a different mechanism, that is, by blocking the VHL:HIF-a
protein-protein interaction downstream of HIF-a hydroxylation.
We show that VH298 engages with VHL as its only major target to
stabilize highly selectively the hydroxylated form of HIF-a in a
concentration- and time-dependent fashion in both cancerous and
non-cancerous primary cells, with subsequent upregulation of
HIF-target genes at mRNA and protein levels.
Results
VH298 is a potent inhibitor of the VHL:HIF-a interaction.
First-generation small molecule disruptors of the VHL:HIF-a
interaction could not induce HIF accumulation inside cells
because of their limited potency27–29. To achieve compound-
induced HIF-a activity and a hypoxic response, inhibitors would
have to bind VHL as strongly as possible to be able to compete
with its high afﬁnity for the endogenous HIF-a substrates inside
cells (Supplementary Fig. 1). We therefore designed VH298,
based on our crystal structure of inhibitor VH032 bound to
VHL30. VH298 bears a cyanocyclopropyl group in place of the
terminal methyl group of VH032 (Fig. 1a). VH298 showed a
Kd of 90 nM as determined by isothermal titration calorimetry
(ITC; Fig. 1c and Table 1) and 80 nM in a competitive
ﬂuorescence polarization assay (Fig. 1d and Table 1), affording
the most potent VHL:HIF-a inhibitor reported to date. This high
afﬁnity corresponds to a ligand efﬁciency of 0.26 that is excellent
for a protein–protein interaction inhibitor31. In addition,
the binding kinetics of the new inhibitor were characterized
by surface plasmon resonance (Fig. 1e). In a dose-dependent
real-time assay VH298 showed a kon of 6.47 105 M 1 s 1
and a koff of 0.065 s 1, indicating fast association and slow
dissociation with VHL complex, respectively (Table 1).
To generate a suitable negative control compound that does
not bind to VHL but maintains as closely as possible the
physicochemical properties of the parent binder, the
cis-hydroxyproline analogue cisVH298 was synthesized
(Table 1). This change in stereochemistry at the carbon atom
bearing the hydroxyl group of the hydroxyproline ring is known
to result in marked loss of binding speciﬁcity of hydroxylated
HIF-1a peptides to VHL in vitro32. As expected, we could not
detect binding of cisVH298 using ITC (Fig. 1c), conﬁrming the
stereospeciﬁc effect is retained in the context of VHL inhibitors.
Crystal structure of VH298 bound to its target protein VHL.
The crystal structure of VH298 bound to the VHL:ElonginB:
ElonginC (VBC) complex (Fig. 1b, stereo view in Supplementary
Fig. 2) was solved to 2.4Å resolution (X-ray data collection,
processing and reﬁnement statistics are in Supplementary Table 1).
VH298 retains the same overall binding mode of VH032 (ref. 30).
The cyanocyclopropyl group ﬁts snugly at the far left-hand side
pocket of the HIF-1a binding site on VHL, with the cyclopropyl
moiety projecting towards the aliphatic side chain of Arg69, and
the cyano group pointing away from the surface and towards
solvent in an anti conformation relative to the amide carbonyl.
This corresponds to a highly favored, minimum energy
conformation for amides substituted with electron withdrawing
groups at the alpha carbon next to the carbonyl, as well
documented for alpha-ﬂuoroamides33,34. This stabilization would
preorganize the ligand in its bound conformation, imparting a
boost in binding afﬁnity. Interestingly, Arg69 adopts a bent
conformation as opposed to the extended conformation observed
in the VH032 bound structure (Supplementary Fig. 3)30. This bent
conformation of Arg69 has been previously observed when a Leu
or tert-Leu group of the inhibitor is occupying the far left-hand
side pocket30, as well as with a bound HIF-1a peptide which bears
a Leu residue at this position13,14, suggesting ﬂexibility of Arg69
could be exploited to accommodate a range of different functional
groups at this left-hand side.
VH298 selectively engages VHL as its prime cellular target. We
next asked whether VH298 could interact with cellular VHL
protein by performing a cellular thermal shift assay35. Protein
levels of both on-target VHL and potential off-target PHD2 were
monitored at different temperatures of incubation in HeLa cell
lysates treated with VH298 using immunoblotting. PHD inhibitor
FG-4592 was used as a control in the assay for PHD2 stabilization.
In the presence of VH298, a signiﬁcant shift in the VHL melting
curve was observed, demonstrating compound-induced target
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stabilization inside cells (Fig. 1f). In contrast, no thermal
stabilization was observed for PHD2 on VH298 treatment
(Fig. 1g). A shift in the melting curve of PHD2, but not VHL, in
the presence of FG-4592 (Fig. 1f–g) conﬁrmed the validity of the
assay. Target engagement and selectivity of VHL inhibitors to VHL
was further supported by chemoproteomic mass spectrometric
results. Quantitative mass-spectrometry analysis of proteins using
isobaric mass tags36 revealed that VHL and other expected
CRL2VHL subunits were captured onto beads derivatized with a
linkable VH298 analogue and selectively displaced by the active
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Figure 1 | Biophysical and structural characterization of VH298, a new potent VHL inhibitor. (a) Chemical structure of VH032 and VH298 inhibitors.
(b) Crystal structure of VBC in complex with VH298 (orange carbons, PDB code 5LLI). VHL is shown as a purple surface and the VHL residues forming the
binding pocket as grey stick representations. The bound ligand is shown as sticks representation with orange carbons, nitrogen atoms in blue, oxygen in red
and sulfur in dark yellow. The inset panel shows the Fo-Fc omit map contoured at 3 s around the ligand. (c) ITC titrations of 300 mM VH298 (blue) and
300mM cisVH298 (green) into 30 mM VBC protein. (d) Competitive ﬂuorescence polarization binding assays of VH298 and VH032 displacing a 20-mer
FAM-labelled HIF-1a peptide binding to VBC (Kd¼ 3 nM), conﬁrming the trend in relative potency observed by ITC (see full data in Table 1). (e) SPR
sensogram of VH298 binding into surface-immobilized VBC. Used ligand concentrations are reported in the inset legend. Cellular thermal shift assays to
monitor cellular target engagement of (f) VHL and (g) PHD2. VH298 and FG-4592 (100mM) were incubated in HeLa cell lysates for 15–30min.
Representative western blots are shown. Data are presented as means±s.e.m. from three independent experiments.
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inhibitor (Supplementary Fig. 4 and Supplementary Data 1), but
not by an inactive analogue (Supplementary Fig. 5). The results
were consistent with those obtained with beads derivatized with
hydroxylated HIF-1a oxygen-degradation domain (ODD) peptides
(Supplementary Fig. 6 and Supplementary Data 2). Although many
proteins were identiﬁed in pull-downs with the derivatized
resin only the bead binding of components of the CRL2VHL
complex was inhibited with increasing concentrations of VHL
inhibitor (Supplementary Fig. 4 and Supplementary Fig. 7). We
also found VH298 to exhibit negligible off-target effects in vitro
against 4100 tested cellular kinases, GPCRs and ion channels, at
50mM concentration (Supplementary Table 2 and Supplementary
Table 3). Altogether, the biophysical, structural and cell-based
in vitro data obtained are consistent with a selective high-afﬁnity
engagement of VH298 with VHL as its main target.
VH298 is cell permeable and not toxic to cells. To evaluate the
cellular activity of VH298, we ﬁrst assessed its cell permeability by
performing PAMPA (parallel artiﬁcial membrane permeability
assay) using a ﬁlter plate pre-coated with structured layers
of phospholipids. We also measured the compounds’ lipophilicity
at physiological pH (LogD7.4) as this property is known to directly
impact on membrane passive permeability37. Higher permeability
promotes an increase of available compound inside cells able
to interact with the desired target. The measured permeability
of VH298 was found to be 19.4nms 1 , which is acceptable
compared with that of high-permeability drug propranolol
(63nm s 1, Table 1). Crucially, the permeability of VH298 was
signiﬁcantly higher than that of VH032 (Table 1), in line with
the increase in LogD7.4, suggesting that VH298 can move through
cell membranes more efﬁciently, leading to an increase on available
inhibitor in cells. We next examined potential cytotoxicity of
VH298 and VH032 in a range of ﬁbroblast, tumoral and non-
tumoral cells. The inactive cis epimers of the two VHL inhibitors
were also tested to assess whether potential inhibitor toxicity might
be due to VHL inhibition or an off-target effect. Pleasingly, the
viability of all cell lines tested was unaffected by compound
treatments up to 150mM concentration, and in most cases even up
to 500mM (Supplementary Fig. 8). The high cell permeability and
negligible cytotoxicity of VH298 afﬁrmed its potential as chemical
probe and warranted evaluation of its biological activity next.
VH298 leads to HIF-a accumulation inside cells. We next asked
whether VH298 could stabilize HIF-a inside. VH298 induced
concentration-dependent accumulation of HIF-1a levels after 2 h
treatments in immortalized HeLa cancer cells (Fig. 2a), with
detectable HIF-1a bands visible as low as 10mM concentration
(Fig. 2a). cisVH298 was inactive even at high concentration
(250mM), demonstrating that the inhibitor’s activity is strictly
dependent on binding to VHL. Beside HIF-1a, HIF-2a was also
stabilized in the presence of VH298 (Fig. 2b). The extent of
VH298-induced HIF-a subunit accumulation after 2 h was
comparable to that observed on treating cells over the same time
with 1% O2 (hypoxia control) or PHD2 inhibitors (IOX2 or
FG-4592) at identical concentrations (100mM) in all cell lines
tested (Fig. 2a–b and Supplementary Fig. 9). Immunoblots
Table 1 | Structures and summary of biophysical, permeability and lipophilicity results for VHL inhibitors.
N
*
HO
O
H
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S
ONH
R
O
Compound R ITC Kd(nM)
FP Kd
(nM)
LE
(kcal mol–1
NHA–1)
SPR Permeability
(PAMPA)
(nm s–1)
CHILogD7.4kon
(M–1 s–1)
koff
(s–1)
VH032 185 ± 6a 150 ± 30 0.28 7.46×105 0.092 1.2 0.90
VH298 90 ± 5 80 ± 20 0.26 6.47×105 0.065 19.4 1.40
cisVH032 NoBinding – – – – 11.7 0.99
cisVH298 NoBinding – – – – 40.8 1.76
NC
H3C
H3C
NC
FP, ﬂuorescence polarization; ITC, isothermal titration calorimetry; SPR, surface plasmon resonance.
The asterisk indicates the stereocenter in the hydroxyproline (Hyp) ring whose inversion to the corresponding cis epimer abolishes binding. Dissociation constants (Kd) were measured by ITC and FP. Ligand
efﬁciencies (LEs) were calculated based on ITC binding results and are deﬁned as binding energy relative to the number of heavy atoms (NHA), LE¼ DGNHA 1¼  RT ln Kd /NHA31. Association (kon)
and dissociation (koff) rate constants were determined by SPR at 10 C. Permeability of inhibitors was determined by PAMPA at room temperature using Atenolol (low permeability—0.0nms 1) and
Propanolol (medium permeability—62.7nms 1) as controls, as described in the Methods section. LogD7.4 values were determined as described in the Methods section a Data from ref. 30.
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with antibodies speciﬁc for HIF-1a hydroxylated at Pro564
(HIF-1a-OH) showed increased levels of this species only on
treatment with VH298 (Fig. 2a–b) and proteasome inhibitor
MG132 (Fig. 2a and Supplementary Fig. 10), but not with
IOX2 and FG–4592 (Fig. 2a–b and Supplementary Fig. 10),
consistent with disruption of the VHL:HIF-a interaction by
VH298 downstream of HIF-a hydroxylation. The same cellular
proﬁle was observed in the presence of two different VHL
inhibitors, VH032 (Kd¼ 185 nM30, Fig. 1a) and VH125
(Kd¼ 280 nM30; Supplementary Fig. 4) but not with inactive
epimers (Supplementary Fig. 10), providing additional evidence for
the compounds’ mechanism of action.
To further evaluate the activity of VHL inhibitors, time-course
experiments with HeLa cells under treatment of VH298 and
hypoxia (1% O2) were performed and levels of HIF-1a and
HIF-2a were independently monitored by immunoblots. VH298
induced a more rapid and pronounced accumulation of HIF-1a
and HIF-2a compared with hypoxia (Fig. 2c) and a long-lasting
buildup of both HIF-1a and HIF-2a (Fig. 2d) in a time-
dependent fashion, with protein levels detectable already after
5min and persisting beyond 24 h after treatment. To conﬁrm that
the increase of HIF-a was indeed due to the inhibition of VHL
activity, clear cell renal cell carcinoma VHL / renal cell
carcinoma 4 (RCC4) cells were treated with VH298. In the
complete absence of functional VHL proteins in RCC4 cells
expressing only the haemagglutinin (HA) tag, the levels of HIF-a
subunits did not increase further on VH298 treatment (Fig. 2b).
In contrast, RCC4 cells expressing HA-tagged VHL showed
accumulation of HIF-a subunits in the presence of VH298
(Fig. 2b and Supplementary Fig. 9), demonstrating the on-target
speciﬁcity of VH298. Taken together, these data provide the ﬁrst
evidence for the stabilization of HIF-a by VHL inhibitors in
tumoral and non-tumoral cell lines, resulting from effective and
speciﬁc blockade of the VHL:HIF-a interaction.
VH298 selectively stabilizes hydroxylated HIF-a. To further
interrogate the speciﬁcity of the compound’s mode of action, we
next asked whether all the stabilized HIF-1a is hydroxylated on
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Figure 2 | VH298 induces concentration- and time-dependent on-target speciﬁc accumulation of hydroxylated HIF-a in human cell lines.
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treatment with VH298. Since the HIF-1a antibody does not dis-
criminate between hydroxylated and non-hydroxylated HIF-1a
species, while the HIF-1a-OH antibody is speciﬁc for the hydro-
xylated species (Fig. 2a–b), we performed immunoprecipitation
experiments with the HIF-1a-OH speciﬁc antibody.
Immunoblotting of HIF-1a after treating cells with VH298 showed
that HIF-1a was found in the immunoprecipitation fractions and
not in the ﬂow-through, consistent with the HIF-1a species
stabilized by VH298 being all of the hydroxylated form (Fig. 2e).
The same result was found when we performed an identical
experiment with the proteasome inhibitor MG132, which also
blocks the pathway downstream of HIF hydroxylation. In contrast,
when cells were treated with the upstream PHD inhibitor
IOX2, HIF-1a was found in the ﬂow-through and not in the
immunoprecipitation fractions, consistent with the HIF-1a
stabilized by IOX2 instead being unhydroxylated (Fig. 2e). Toge-
ther these results are consistent with VH298 blocking VHL E3
ubiquitin ligase downstream of HIF hydroxylation, leading to
speciﬁc intracellular accumulation of the hydroxylated HIF-a
form.
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Figure 3 | VHL inhibitors induce HIF-a transcriptional activity in various cell lines. (a) U2OS cells stably expressing an HRE-luciferase reporter plasmid
were treated with indicated conditions for 32 h. (b) Dose-response curves of CA9 and GLUT1 mRNA expressions in HFF (24 h), HeLa (16 h), U2OS (16 h)
and CTL (6 h) cells in the presence of cisVH032, cisVH298, VH032 and VH298. mRNA was collected, reverse transcribed and analysed by qRT-PCR. The
shown levels of the indicated mRNAs were normalized to those of b-actin, except for CTLs where they were normalized to the levels of TATA-binding
protein mRNA. (c) EPO production in RCC4-HA and RCC4-HA-VHL cells subjected to 150mM VH298. Graphs depict the meanþ s.e.m. of three
independent biological replicates. Student’s t-test was performed to calculate P values, and levels of signiﬁcance are denoted as follows: *Po0.05,
**Po0.01 and, ***Po0.001.
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VH298 induces HIF transcriptional activity. To assess the
ability of VHL inhibitors to promote HIF activity, we ﬁrst used a
luciferase reporter assay38. In HRE-luciferase reporter cells,
U2OS-HRE, treatments with VHL inhibitors exhibited marked
concentration-dependent increase of HIF-dependent luciferase
activity, consistent with hypoxia and IOX2 treatments, while no
activity was observed with high concentration of non-binding
epimers (Fig. 3a). Corresponding to VH298 being more potent
and more cell-permeable than VH032 (Table 1), VH298 required
a lower concentration (50 mM) than VH032 (150 mM) to reach the
same level (threefold increase relative to control) of HIF activity
in U2OS cells (Fig. 3a). VH298 induced detectable HIF activity at
10 mM concentration (Fig. 3a). The more potent cellular activity
of VH298 compared with VH032 was further conﬁrmed in a
qRT–PCR assay (Fig. 3b) monitoring mRNA levels of known
HIF-target genes including CA9, GLUT1 and PHD2 in different
cellular backgrounds. Treatments with VH032 and VH298
showed marked upregulation of HIF-target genes, but not with
inactive epimers cis-VH032 and cis-VH298 (Fig. 3b). Different
responses to VHL inhibitor treatment were observed in
different cell lines. For instance, HFF was the most sensitive to
VHL inhibitors among the cell lines used; maximum mRNA
levels of CA9 and GLUT1 were reached with 100 and 25 mM of
VH298, respectively, in HFF cells. Consistently in all cell lines, a
lower concentration of VH298 than VH032 was required to
increase mRNA levels of target genes to the same level. These
results indicate that VHL inhibitor-induced hydroxylated HIF
proteins are transcriptionally active and conﬁrm the superiority
of VH298 over previously reported VHL inhibitors as a chemical
probe.
VH298 stimulates EPO production in a VHL-dependent manner.
HIF transcriptional activities are known to stimulate the
production of the hormone erythropoietin (EPO), which is
primarily expressed in the kidney and liver39. To investigate
whether VH298-induced HIF activity is able to stimulate EPO
production, EPO mRNA levels in RCC4 cells reconstituted
with HA-tag or HA-VHL tag were analysed by qRT–PCR. VH298
increased mRNA levels of EPO by 2.5-fold in RCC4-HA-VHL,
but not in VHL-null RCC4-HA (Fig. 3c), indicating that
pharmacological inhibition of VHL is able to stimulate
endogenous EPO synthesis.
VH298 upregulates HIF-dependent response gene products.
To examine whether the observed VH298-dependent increases
of HIF target mRNAs would be translated into proteins, we
monitored protein levels of known HIF target gene products
(CA9, GLUT1, PHD2, PHD3, BNIP3 (ref. 40) and HK2) in
mammalian cells treated for 24 h with VH298 or PHD inhibitors
IOX2 and FG-4592 (each at concentration of 100 mM), or hypoxia
(1% O2). The protein levels of GLUT1 were monitored in
cytotoxic T lymphocyte (CTL) cells as GLUT1 is a known HIF-1a
target gene in these cells41. Corresponding to the stabilized HIF
subunits, accumulation of all the HIF targets was detected
following prolonged treatment of VH298 in cells, consistent to
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Figure 4 | VH298 elicits a HIF-dependent hypoxic response in various cell lines. 1% DMSO, hypoxia (1% O2) and indicated compounds at 100mM were
introduced to (a) HFF, HeLa, U2OS and (b) RCC4 cells expressing HA-tagged VHL (with the exception of cis-VH298 and VH298 used at 150 mM) for 24 h
and (c) CTLs for 8 h. Protein levels were analysed by immunoblotting using antibodies against the indicated proteins, with b-actin (SMC1 for CTLs) as the
loading control. The blots shown are representative of three independent experiments.
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hypoxia or PHD inhibition treatments (Fig. 4a–c). In all cell lines
tested, many of the HIF targets screened were increased the most
in the hypoxia condition, with GLUT1 and CA9 being the
most prominent (Fig. 4a–c). PHD3 was also upregulated the
most under hypoxia in most cell lines (Fig. 4a,c), but not in
RCC4-HA-VHL, in which PHD3 levels were not affected by any
treatments (Fig. 4b). VH298 proved as effective as hypoxia in
raising PHD2 and HK2 protein levels (Fig. 4a–b), however in
HFF the BNIP3 protein level increased more with VH298
treatment than hypoxia treatment. By contrast, most target
proteins were upregulated by VH298 to similar levels when
compared with PHD inhibition in all cell lines tested (Fig. 4a–b).
The exception was RCC4-HA-VHL cells, in which IOX2 and
FG-4592 treatments were the most effective conditions, as
observed by higher levels of target proteins, including CA9,
PHD2, BNIP3 and HK2 (Fig. 4b). Unlike in other cell lines, a
higher concentration (150 mM) of VH298 was introduced to
RCC4-HA-VHL cells to detect a good response to VHL
inhibition, which was likely due to the high level of HA-tagged
VHL expressed in the VHL-null RCC4 cells (Supplementary
Fig. 11). The data presented support the application of VH298 as
chemical probe that elicits effective HIF-dependent hypoxic
response inside cells.
Discussion
Chemical probes that target speciﬁc gene products at the
post-translational level, rather than at the DNA or RNA level,
offer attractive advantages over gene knock-outs and RNA
interference; including allowing spatial and temporal control,
convenience of delivery, stability and reversibility of action, and
the ability to address different post-translational isoforms or
modiﬁcation states. Target inhibition by a chemical probe is also
mechanistically different from target knockout or knockdown,
and as a result often leads to different phenotypic outcomes.
Chemical probes are, therefore, complementary to genetic tools in
that they allow addressing biological questions about the
molecular target in different ways, often leading to new insights2.
Genetic knockouts and knockdown to inactivate VHL have
been widely used in biochemical research. While homozygous
VHL / mice are embryonically lethal and not viable42,
heterozygous and conditional tissue-speciﬁc VHL knockouts43,
as well as VHL small interfering RNA44, have provided useful
tools shining important insights in the biological consequences of
VHL inactivation and subsequent HIF upregulation in cancer45,
immunology and inﬂammation46, and aging47. However, the
functional consequences of blocking the VHL:HIF-a interaction
with small molecules inside cells had to date remained elusive and
limited to early studies using ectopically expressed or TAT-fused
ODD polypeptide sequences48. Here we describe a different
approach to HIF stabilization and hypoxic response, through the
targeting of VHL using the potent and cell-penetrant small
molecule VH298 that disrupts the interaction of VHL with
HIF-a. We report systematic proﬁling of VH298 in cells, not only
in terms of speciﬁcity of mechanism of inhibition, but also
potency, target engagement and exposure, and selectivity. Our
data provide strong cellular validation for the application of VHL
inhibitors as chemical probes to study speciﬁc roles of VHL and
hydroxylated HIF-a in biology, which could help to dissect
HIF-dependent functions of VHL from HIF-independent
functions49.
Disruption of VHL function in VHL disease mutations of the
von Hippel–Lindau syndrome or in VHL / RCC leads to
constitutive stabilization and upregulation of HIF-a even in the
absence of hypoxia, driving pro-angiogenic transcription45,50,51.
In contrast to the roles of HIF in renal cell carcinoma
tumorigenesis, its pharmacological stabilization under normoxic
conditions could provide therapeutic beneﬁt for many conditions
including anemia due to chronic kidney disease and anemia
associated to cancer chemotherapy52, ischemia and ischemic
reperfusion injuries in the kidney, brain, heart or liver53,54, acute
lung injuries55 and intestinal inﬂammation56. Recent studies have
also identiﬁed VHL knockdown/knockout as protective during
states of mitochondrial dysfunction, supporting VHL and PHD
inhibition as a potential treatment for human diseases associated
with mitochondrial respiratory chain dysfunction57. Over the
years, a number of strategies have been developed to stabilize
HIF-a through escaping or blocking its degradation by the
proteasome, with the most promising being the inhibition of
HIF-a hydroxylation catalysed by PHDs58. Five PHD inhibitors
(BAY-853934, JTZ-951, FG-4592, AKB-6548 and GSK1278863)
have entered clinical trials, with the most advanced (FG-4592)
being in Phase III trials to treat anemia in patients with chronic
kidney disease23. PHD inhibitors have shown clinical efﬁcacy in
Phase II trials, and have largely proved safe, thus validating the
hypoxic signalling pathway as a drug target for these conditions3.
However, side- and off-target effects of PHD inhibitors have
raised concerns about their safety and tolerability as therapies
for human patients, as exempliﬁed by the failure of early
candidate FG-2216 that caused fatal hepatic necrosis59. Three
PHD isoenzymes are known (PHD1, PHD2 and PHD3) that
have different substrate speciﬁcities and different subcellular and
tissular expression60. In addition, other substrates of PHDs have
been identiﬁed beyond HIF, including Cep192, RNA polymerase
and the b-adrenergic receptor60,61. Potent and highly selective
VHL inhibitors represent an attractive alternative to PHD
inhibitors as HIF-stabilizing agents with a different mechanism
of action, which may alleviate potential HIF-independent
undesired effects of PHD inhibitors. In addition, VH298 is also
able to stimulate the production of endogenous EPO (Fig. 3c),
indicating its potential to beneﬁt patients with anemia resulting
from insufﬁcient EPO synthesis39. Our data disclosing VHL
inhibitors as new chemical probes of hypoxic signalling warrant
further lead optimization and investigation of compound
bioavailability, stability and efﬁcacy in vivo to exploit the full
therapeutic potential of this class of compounds in future.
While maximizing HIF-stabilizing activity is desirable for the
therapeutic purpose of developing VHL inhibitors in their own
right, the opposite holds true in the context of proteolysis targeting
chimeras (PROTACs)62. PROTACs are heterobifunctional
compounds in which a small molecule binding to a Cullin-RING
E3 ligase63 can be chemically linked to another ligand to induce
intracellular degradation of a speciﬁc target protein64. Recent
studies have reported promising biological efﬁcacies in cells and
in vivo against a range of targets with different PROTACs
recruiting the VHL E3 ligase, many using VH032 as the
VHL ligand65,66. In this context, it is important that compounds
do not induce a HIF-dependent response, which would otherwise
confound or interfere with the desired biological effect resulting
from induced target knockdown. The results of this study reveal an
exploitable concentration window between the desired PROTAC
activity (observed in the pM-nM range65–67) and the
HIF-stabilizing activity (observed in the mM range with VHL
inhibitors, documented here).
In summary, we describe and characterize VH298 as a potent
and selective VHL inhibitor that triggers a functional dose-
dependent response downstream of HIF-a hydroxylation in the
hypoxia-signalling cascade inside cells. This is to our knowledge the
ﬁrst report to date of selective pharmacological stabilization of the
hydroxylated form of HIF-a using small molecules chemical probes
to drive a HIF-dependent hypoxic response. Relevant information
to the use of VH298 as a new chemical probe of the hypoxic
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signalling pathway will be deposited in the newly established
‘Chemical Probes Portal’ (http://www.chemicalprobes.org/)2 for the
beneﬁt of the scientiﬁc community. We anticipate that the data
reported in this study and the availability of the compound will aid
wide acceptance and use by the community and lead to many new
advances in the hypoxia ﬁeld.
Methods
Synthesis of VH298. Synthetic methods are included in the Supplementary
Methods of the Supporting Information.
Isothermal titration calorimetry. ITC experiments were carried in an ITC200
micro-calorimeter (GE Healthcare), as previously described30.
Fluorescence polarization. Fluorescence polarization competitive binding
experiments were performed on a PHERAstar FS (BMG LABTECH) in 384-well
plates (Corning 3575), with l excitation at 485 nm and l emission at 520 nm.
Each well solution (15 ml) contained 15 nM of VBC protein, 10 nM of
5,6-Carboxyﬂuorescein (FAM) labelled HIF-1a peptide (FAM-DEALAHyp-
YIPMDDDFQLRSF, Kd¼ 3 nM as measured by a direct ﬂuorescence polarization
titration) and decreasing concentrations of compound (13-point serial two-fold
dilutions starting from 50mM), in 100mM Bis-tris, 100mM NaCl, 1mM DTT,
pH 7. Control wells contained VBC and peptide in the absence of compound
(maximum signal), and peptide in the absence of protein (background signal).
Data were obtained in triplicate and ﬁtted using a four-parameter dose-response
model using the PHERAstar Mars software provided by the manufacturer. The
average IC50 and the standard error of the mean (SEM) were determined for each
titration. Dissociation constants Kd were back-calculated from the measured IC50
values using a displacement binding model, as previously described28.
Surface plasmon resonance. Compound VH298 was dissolved in
dimethylsulfoxide (DMSO) (1mM) and then diluted 20 fold in DMSO to achieve a
50mM ﬁnal stock concentration. Ligand stock solution was diluted twofold
(ﬁve times) in DMSO and the obtained solutions were then diluted individually in
surface plasmon resonance buffer (20mM HEPES, 150mM NaCl, 1mM DDT,
0.005% Tween P20, pH 7.0) to obtain the ﬁnal 2% DMSO concentration series
from 1 mM to 31.25 nM (two-fold dilutions) and transferred to a 96-well plate. The
experiment was conducted in a Biacore T100 (GE Healthcare, Biacore, Uppsala,
Sweden) at 10 C and solutions were injected individually using 60 s and 160 s
association and dissociation times, respectively. Data were treated using a Biacore
T100 Evaluation Software provided by the manufacturer. Reference ﬂow cell
response was subtracted from the sample response with immobilized VBC protein
to correct for systematic noise and baseline drift. Data were solvent corrected and
the response from the blank injections was used to double reference the binding
data. The data were molecular weight normalized and kon/koff values were obtained
using a 1:1 binding model ﬁt.
Crystal structure of the VBC:VH298 complex. The VBC ternary complex was
puriﬁed and crystallized as described previously28,30. Equal volume solutions of
VBC (B5mgml l) and liquor solution were mixed in the hanging-drop vapor
diffusion method at 18 C. The liquor solution contained 0.1mM sodium
cacodylate, pH 6.4, 16% polyethylene glycol 3,350, 0.2M magnesium acetate and
10mM DTT. The drop was streaked with seeds of disrupted VBC crystals and a
2–3mm layer of Al’s Oil (Hampton Research) was applied on top of the liquor
solution to slow the vapour diffusion rate. To obtain a structure of VH298 bound
to VBC, crystals were soaked overnight in a 1mM solution of inhibitor in 1%
DMSO, 4% isopropanol and 95% liquor solution. Crystals were screened using an
in-house Rigaku M007HF X-ray generator and Saturn 944HGþ CCD detector.
X-ray data were collected at 100 K at Diamond Light Source beamline I04-1.
Indexing and integration of reﬂections was performed using XDS with the
XDSGUI interface68, and scaling and merging with AIMLESS in CCP4i69,70. The
isomorphous datasets were reﬁned using REFMAC5 (refs 71,72) and COOT73
using a template structure derived from the Protein Data Bank (PDB) entry 1VCB9.
Ligand structures and restraints were generated using the PRODRG server74.
The MOLPROBITY server was used to validate the geometry and steric clashes in
the structures75. The data collection and reﬁnement statistics are presented in
Supplementary Table 1.
Cell culture and hypoxia induction. Human cell lines HFF, HeLa, U2OS,
RCC4-HA and RCC4-HA-VHL were obtained from ATCC and propagated in
DMEM supplemented with 10% fetal bovine serum (FBS), L-glutamine,
100mgml l of penicillin/streptomycin) at 37 C. RCC4-HA and RCC4-HA-VHL
were maintain in 400 mgml 1 G418. U2OS-HRE luciferase cells were as
described76 and maintained in 0.1 mgml 1 puromycin. All cell lines were routinely
tested for mycoplasma contamination using MycoAlert kit from Lonza. Primary
mouse CTLs were generated and cultured as described previously77. Brieﬂy,
lymphocytes isolated from spleens of nontransgenic mice were activated for 48 h
with 0.5 mgml 1 of anti-CD3 (2c11) and 4 ngml 1 of anti-CD28 and 20 ngml 1
of IL-2 (Proleukin) and then maintained in the culture for additional 5 days in
20 ngml 1 of IL-2. For hypoxia induction, cells were incubated at 1% O2 in an
InVIVO 300 hypoxia workstation (Ruskin Technologies). To prevent
reoxygenation, cells were lysed for protein extraction in the hypoxia workstation.
Immunoblotting. Cells were lysed in RIPA buffer (50mM Tris pH 8, 150mM
NaCl, 1% NP-40, 0.5% sodium deoxycholate, 0.1% SDS), 250M Na3VO4, 10mM
NaF, and a protease inhibitor cocktail (Roche) per 10ml buffer. CTL cells were
lysed at 2 106 in Tris lysis buffer containing 10mM Tris, pH 7.05, 50mM NaCl,
30mM Na pyrophosphate, 50mM NaF, 5 mM ZnCl2, 10% glycerol, 0.5% Triton,
1mM neutralized TCEP and protease inhibitors (Roche). Proteins were resolved
using sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS–PAGE),
transferred onto polyvinylidene diﬂuoride membranes and detected using primary
antibodies, with b-actin and SMC1 as loading controls in mammalian cells and
CTLs, respectively.
Primary antibodies were used at following dilutions for mammalian cells:
anti-HIF-1a (BD Biosciences; 610958; 1:1,000), anti-hydroxy-HIF-1a (Hyp564)
(Cell Signaling Techonology; #3434; 1:1,000), anti-HIF-2a (R&D; AF 2886;
1:1,000), anti-CA9 (Novus Biologicals; NB100-417; 1:1,000), anti-GLUT-1
(Cell Signaling Techonology; CS 129395; 1:1000), anti-PHD2 (Bethyl Laboratories;
A300-322A; 1:1,000), anti-PHD3 (Bethyl Laboratories; A300-327A; 1:1,000),
anti-BNIP3 (abcam; ab10433; 1:10,000), anti-VHL (Cell Signaling Techonology;
#2738; 1:1,000) anti-b-actin (Cell Signaling Techonology; #3700s; 1:10,000).
Primary antibodies were used at following dilutions for CTLs: anti-HIF-1a
(R&D; MAB1536; 1:500), anti-GLUT-1 (Cell Signaling Techonology; CS 129395;
1:1,000) and anti-SMC1 (Bethyl Laboratories, Inc.; A300-055A 1: 10,000).
Following incubation with a horseradish peroxidase-conjugated secondary
antibody (Cell Signaling Techonology), chemiluminescence (Thermo Scientiﬁc)
was used for immunodetection.
Chemoproteomics. HeLa cells were purchased from ATCC and cultured in MEM
supplemented with 1mM pyruvate, 0.1mM nonessential amino acids and 10% FCS
at 37 C, 5% CO2. Cell pellets were homogenized in lysis buffer (50mM Tris-HCl,
0.8% Igepal-CA630, 5% glycerol, 150mM NaCl, 1.5mMMgCl2, 25mM NaF, 1mM
Na3VO4, 1mM DTT, pH 7.5). One complete EDTA-free protease inhibitor tablet
(Roche) per 25ml was added. The sample was dispersed using a Dounce
homogenizer, kept rotating for 30min at 4 C and spun for 10min at 20,000 g at
4 C. The supernatant was spun again for 1 h at 145,000 g. The protein
concentration was determined by Bradford assay (BioRad), and aliquots were snap
frozen in liquid nitrogen and stored at  80 C.
For peptide pull-down experiments, biotinylated HIF-1a CODD and NODD
19-mer Hyp-modiﬁed peptides (NODD: Hyp402, CODD: Hyp564) or unmodiﬁed,
harbouring aminohexanoic acid (ahx) as spacer after the biotin (NODD:
biotin-ahx-DALTLLA-(Hyp/P)-AAGDTIISLDF-amide; CODD: biotin-ahx-
DEALA-(Hyp/P)-YIPMDDDFQLRSF-amide) were immobilized on high capacity
Neutravidin beads.
For compound pull-down experiments, sepharose beads were derivatized with
0.1mM VH125 bearing a free terminal amino group (NH2-VH125) essentially as
described36.
Competition experiments were performed by spiking increasing concentration
of compound or vehicle control into HeLa cell lysates and incubating for 45min at
4 C. Subsequently, beads were added and incubated for 2 h at 4 C. After washing,
bound proteins were eluted with SDS-sample buffer and prepared for tandem mass
tags labelling and MS analysis as described36. Samples were dried in vacuo,
resuspended in 0.1% formic acid in water and injected into a Dionex Ultimate 3000
UHPLC coupled to Orbitrap mass spectrometers (Thermo Fisher Scientiﬁc).
Mascot 2.4.1 (Matrix Science) was used for protein identiﬁcation, using 10 ppm
mass tolerance for peptide precursors and 20mDa (HCD) mass tolerance for
fragment ions. Protein identiﬁcation and data processing for quantiﬁcation were
performed as described36. Aliquots of the eluates from the pull-downs experiments
were used for western blot analysis and anti-VHL mouse antibodies (BD
Pharmingen #556347) used for detection.
Cellular thermal shift assay. HeLa cells were harvested with trypsin/EDTA,
suspended in PBS supplemented with protease inhibitor cocktail (Thermo
Scientiﬁc) and lysed by four freeze-thaw cycles in dry ice/ethanol bath. The soluble
fraction (lysate) was separated from the cell debris by centrifugation at 17,000g for
20min at 4 C. The lysate was divided into two aliquots, with one aliquot being
treated with 100 mM of VH298 or 100 mM of FG-4592 and the other aliquot with
vehicle (1% DMSO). After 10-30min incubation at room temperature, the two
fractions were divided into smaller aliquots (50 ml) and heated individually at
different temperatures for 3min followed by cooling for 3min at room
temperature. The heated lysates were centrifuged at 17,000 g for 20min at 4 C,
and the soluble fractions were analysed by SDS-PAGE and immunoblotted for
anti-VHL (Cell Signaling Techonology) and anti-PHD2 (Bethyl Laboratories). Raw
images were analysed using ImageJ. Data quantiﬁed relative to control samples
incubated at the lowest temperature (40.4 C).
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Co-immunonoprecipitation. HeLa cells were lysed in 1% Triton X-100, 20mM
Tris (pH 7.5), 150mM NaCl, and one tablet of EDTA-free complete protease
inhibitor mix (Roche) per 10ml buffer. 300 mg of cell lysates were used per
immunoprecipitation condition. Protein lysates were incubated with 1 mg of
HIF-1a-OH antibody (Hydroxy-HIF-1a (Pro564), Cell Signaling Techonology) or
3 mg of rabbit IgG control antibody (Sigma) in a rotating platform at 4 C over-
night. 20 ml of packed protein-G-sepharose beads (Pierce) were used to recover the
immuno-complexes, by incubation in a rotating platform for 1.5 h at 4 C. Lysates
were collected as ﬂow through (FT) before 5 washes with 0.1% Tween-20 in
1 PBS buffer. The complexes were eluted from beads with SDS loading buffer
and resolved as described above by immunoblotting.
Parallel artiﬁcial membrane permeability assay (PAMPA). PAMPA was per-
formed using a 96-well pre-coated BD Gentest PAMPA plate (BD Biosciences,
UK). Each well was divided into two chambers: donor and acceptor, separated by a
lipid-oil-lipid tri-layer constructed in a porous ﬁlter. The effective permeability, Pe,
of the compound was measured at pH 7.4. Stock solutions (5mM) of the
compound were prepared in DMSO. The compound was then further diluted to
10mM in PBS, pH 7.4. The ﬁnal DMSO concentration did not exceed 5% v/v. The
compound dissolved in PBS was then added to the donor side of the membrane
and PBS without compound was added to the acceptor side. The PAMPA plate was
left at room temperature for 5 h, after which time, an aliquot (100 ml) was removed
from both acceptor and donor compartments and mixed with acetonitrile (80 ml)
containing an internal standard. The samples were centrifuged (10min, 5 C,
3270 g) to sediment precipitated protein and sealed before ultra-performance
liquid chromatography tandem mass-spectrometry (UPLC-MS/MS) analysis using
a Quattro Premier XE (Waters Corp, USA). Pe was calculated as shown in the
below equation:
Pe nm s
 1 ¼ 107 In 1CA tð Þ=Cequi
 
A 1=VD þ 1=VAð Þt
 
ð1Þ
Where:
CA(t)¼ peak area of compound present in acceptor well at time t¼ 18,000 s
Cequi¼ [CD(t)VDþCA(t)VA]/(VDþVA)
CD(t)¼ peak area of compound present in donor well at time t¼ 18,000 s
A¼ ﬁlter area
VD¼ donor well volume
VA¼ acceptor well volume
t¼ incubation time
Recovery of compound from donor and acceptor wells was calculated and data
was only accepted when recovery exceeded 70%.
CHIlogD7.4 measurement. The CHIlogD (chromatographic hydrophobicity
index logD) at pH 7.4 was determined using retention time measurements on a
HPLC Dionex system (Thermo Fisher) with a Luna C18 column (Phenomenex).
Test samples in DMSO (10mM) were diluted to a concentration of 0.25mM using
50:50 acetonitrile:water. Mobile phase A was 10mM ammonium acetate solution
(pH 7.4) and mobile phase B was acetonitrile. HPLC method was as follows:
1mlmin 1 ﬂow, temperature 20C, injection volume 10ml, gradient: 0 to 10.5min
100% A, 10.5 to 14min 100% B, 14 to 15min 100% A. A calibration line was
generated using a test mix of compounds (paracetamol, theophylline,
caffeine, benzimidiazole, colchicine, carbamazepine, indole, propiophenone,
butyrophenone, valerophenone and heptanophenone). The CHIlogD was
calculated as previously described78,79.
Cytotoxicity assay for mammalian cells. Cell viability was analysed using
CellTiter-Glo Luminescent Cell Viability Assay (Promega). Cells were plated in
384-well plates (1,000 RCC4 cells per well and 1,500 HFF, HeLa or U2OS cells per
well) one day prior and treated with VHL inhibitors and respective non-binding
cis-analogues for 24 h. Cells were incubated with CellTiter-Glo reagent according to
the manufacturer’s protocol and luminescence was measured using PHERASTAR
machine.
Cytotoxicity assay for CTLs. Death of CTLs was analysed by staining with
40 ,6-diamidino-2-phenylindole (DAPI). Cells were plated in 96-well plates at
1 106 and treated with VHL inhibitors and respective non-binding cis-analogues
for 24 h. Next, cells were spun down and re-suspended in HBSS containing DAPI
to identify dead and dying populations. Data were acquired on FACSVerse
machine (Becton Dickinson) and analysed using FlowJo software (TreeStar).
Luciferase assay. U2OS cells stably express HRE-luciferase reporter were treated
with indicated compounds in fresh medium for 32 h. Cells were lysed in passive
lysis buffer (Promega), and luciferase assays were performed according to the
manufacturer’s instructions (Promega) and activity was measured using Berthold
Lumat LB 9507 Luminometer. Results were normalized for protein concentration
with all experiments being performed a minimum of three times before calculating
means and s.d.s.
Quantitative real-time PCR. Mammalian cells: RNA was extracted using the
RNeasy Mini Kit (Qiagen) according to manufacturer’s protocol. RNA was reverse
transcribed using the iScript cDNA Synthesis kit (Bio-Rad). Real-time PCR was
performed in triplicates using PerfeCTa SYBR Green FastMix (Quanta Biosciences)
in C1000 Touch Thermal Cycler (Bio-Rad Laboratories). mRNA levels were
calculated based on averaged CT values and normalized to b-actin mRNA levels.
CTLs: RNA was extracted using the RNeasy Mini Kit (Qiagen) according to
manufacturer’s protocol. RNA was reverse transcribed using the qScript cDNA
synthesis kit (Quanta). Real time PCR was performed in triplicates using SYBR
Premix Ex Taq II (2 ) (TaKaRa) in C1000 Thermal Cycler (Bio-Rad
Laboratories). mRNA levels were calculated based on averaged CT values and
normalized to TATA-binding protein (TBP) mRNA levels.
Primer sequences are available in the Supplementary Methods of the
Supporting Information.
Data availability. Data supporting the ﬁndings of this study are available
within the article (and its Supplementary Information ﬁles) and from the
corresponding author on reasonable request. Coordinates and structure factors
have been deposited in the Protein Data Bank (PDB) with the accession code 5LLI.
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